VSTM vs. XOMA, RIGL, VNDA, MACK, EBS, LXRX, OPK, INVA, RAPT, and NBTX
Should you be buying Verastem stock or one of its competitors? The main competitors of Verastem include XOMA (XOMA), Rigel Pharmaceuticals (RIGL), Vanda Pharmaceuticals (VNDA), Merrimack Pharmaceuticals (MACK), Emergent BioSolutions (EBS), Lexicon Pharmaceuticals (LXRX), OPKO Health (OPK), Innoviva (INVA), RAPT Therapeutics (RAPT), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical preparations" industry.
XOMA (NASDAQ:XOMA) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.
Verastem has a net margin of 0.00% compared to Verastem's net margin of -886.91%. Verastem's return on equity of -25.17% beat XOMA's return on equity.
Verastem received 168 more outperform votes than XOMA when rated by MarketBeat users. However, 65.74% of users gave XOMA an outperform vote while only 65.20% of users gave Verastem an outperform vote.
In the previous week, Verastem had 3 more articles in the media than XOMA. MarketBeat recorded 5 mentions for Verastem and 2 mentions for XOMA. Verastem's average media sentiment score of 0.97 beat XOMA's score of 0.08 indicating that XOMA is being referred to more favorably in the media.
95.9% of XOMA shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 5.2% of XOMA shares are owned by insiders. Comparatively, 2.9% of Verastem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
XOMA has higher revenue and earnings than Verastem. XOMA is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.
XOMA presently has a consensus target price of $74.00, suggesting a potential upside of 207.69%. Verastem has a consensus target price of $28.79, suggesting a potential upside of 143.95%. Given Verastem's higher probable upside, equities research analysts plainly believe XOMA is more favorable than Verastem.
XOMA has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Verastem has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500.
Summary
XOMA beats Verastem on 11 of the 17 factors compared between the two stocks.
Get Verastem News Delivered to You Automatically
Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Verastem Competitors List
Related Companies and Tools